MedTrace Logo

Rhodiola Rosea Therapy of Major Depressive Disorder

NCT01098318 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2018-02-22

Study results available
· View outcomes & findings →

Summary

Prior research has shown that Rhodiola rosea may be an effective, short-term, anti-depressant therapy. This study will examine the anti-depressant effect of Rhodiola rosea vs. a conventional, anti-depressant drug in the treatment of major depression.

Conditions

Interventions

DIETARY_SUPPLEMENT

Herbal extract

340-1,360 mg daily

DRUG

Sertraline

50-200 mg daily

OTHER

Lactose monohydrate

1-4 capsules daily

Sponsors & Collaborators

Principal Investigators

  • Jun J. Mao, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01098318 on ClinicalTrials.gov